Outlook Therapeutics Aims for $500M U.S. Sales by 2030 After FDA Approval of LYTENAVA — Outlook Therapeutics, Inc.

Event summary

Outlook Therapeutics' CEO Bob Jahr discussed the FDA approval of LYTENAVA in a Virtual Investor CEO Connect segment on September 10, 2026.
LYTENAVA is the only FDA-approved ophthalmic formulation of bevacizumab for wet AMD in the U.S.
The company aims to achieve over $500 million in annual U.S. sales by 2030.
Outlook Therapeutics plans to launch LYTENAVA in the U.S. before the end of 2026.
The company is leveraging its European commercialization experience for its U.S. launch strategy.

The big picture

Outlook Therapeutics' transition to a commercial-stage company with the FDA approval of LYTENAVA positions it to capture a significant share of the U.S. retina market. The company's focus on shifting existing off-label use to its approved product highlights a strategic opportunity in a market where bevacizumab has been widely used but lacked a dedicated ophthalmic formulation. The success of this transition will depend on effective market access, reimbursement, and physician education strategies.

What we're watching

Market Adoption: How quickly physicians and patients will shift from off-label use of bevacizumab to LYTENAVA.
Execution Risk: Whether Outlook Therapeutics can successfully execute its U.S. launch strategy given its experience in Europe.
Revenue Growth: The pace at which the company can achieve its $500 million annual sales target by 2030.